We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

The quick answer is that dosing for semaglutide varies by whether you take Ozempic, Wegovy, Rybelsus ... Additionally, it could increase the conversion of white fat to brown fat.

We obviously, rolled out Zepbound and this is -- we're just now ... the patients lose weight, does it convert to long-term health benefit? The answer now, yes. Those are in submission review ...

Four GLP-1 receptor agonists have been approved for obesity treatment: Novo Nordisk’s Wegovy and Saxenda, Eli Lilly’s Zepbound ... the devices required to convert these into products ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy to help add $20 billion to the value of the market in a decade. After a fallow period ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, according to the chief executive officer of Zealand Pharma A/S ...